Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

O Rascol

Showing results (101-110 of 220) with videos related to

Pageof 22
Sort By:
Movement Disorders : Official Journal of the Movement Disorder Society|May 1, 1995
Does fluoxetine aggravate Parkinson's disease? A pilot prospective studyJ L Montastruc, N Fabre, O Blin, et al.
Journal of Neurochemistry|September 1, 1992
Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin content?A Kastner, E C Hirsch, O Lejeune, et al.
Therapie|January 1, 1994
[Apropos of secondary effects of hydroxyzine]P Pascali, F Sorbette, J M Senard, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|March 21, 2000
Neural substrate for the effects of passive training on sensorimotor cortical representation: a study with functional magnetic resonance imaging in healthy subjectsC Carel, I Loubinoux, K Boulanouar, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|July 1, 1991
Square wave jerks in parkinsonian syndromesO Rascol, U Sabatini, M Simonetta-Moreau, et al.
Drugs|November 1, 1995
Antivertigo medications and drug-induced vertigo. A pharmacological reviewO Rascol, T C Hain, C Brefel, et al.
Clinical Neuropharmacology|April 1, 1989
Alpha 2-adrenergic sensitivity in Parkinson's diseaseM Berlan, O Rascol, J Belin, et al.
Neurology|September 1, 1988
Two weeks of treatment with deprenyl (selegiline) does not prolong L-dopa effect in parkinsonian patients: a double-blind cross-over placebo-controlled trialO Rascol, J L Montastruc, J M Senard, et al.
Lancet (London, England)|March 16, 2005
Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trialO Rascol, D J Brooks, E Melamed, et al.
Clinical Neuropharmacology|February 27, 1999
L-Dopa-induced sedation: a double-blind cross-over controlled study versus triazolam and placebo in healthy volunteersN Andreu, J J Chalé, J M Senard, et al.
Pageof 22

Showing results (101-110 of 220) with videos related to

Sort By:
Pageof 22
Movement Disorders : Official Journal of the Movement Disorder Society|May 1, 1995
Does fluoxetine aggravate Parkinson's disease? A pilot prospective studyJ L Montastruc, N Fabre, O Blin, et al.
Journal of Neurochemistry|September 1, 1992
Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin content?A Kastner, E C Hirsch, O Lejeune, et al.
Therapie|January 1, 1994
[Apropos of secondary effects of hydroxyzine]P Pascali, F Sorbette, J M Senard, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|March 21, 2000
Neural substrate for the effects of passive training on sensorimotor cortical representation: a study with functional magnetic resonance imaging in healthy subjectsC Carel, I Loubinoux, K Boulanouar, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|July 1, 1991
Square wave jerks in parkinsonian syndromesO Rascol, U Sabatini, M Simonetta-Moreau, et al.
Drugs|November 1, 1995
Antivertigo medications and drug-induced vertigo. A pharmacological reviewO Rascol, T C Hain, C Brefel, et al.
Clinical Neuropharmacology|April 1, 1989
Alpha 2-adrenergic sensitivity in Parkinson's diseaseM Berlan, O Rascol, J Belin, et al.
Neurology|September 1, 1988
Two weeks of treatment with deprenyl (selegiline) does not prolong L-dopa effect in parkinsonian patients: a double-blind cross-over placebo-controlled trialO Rascol, J L Montastruc, J M Senard, et al.
Lancet (London, England)|March 16, 2005
Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trialO Rascol, D J Brooks, E Melamed, et al.
Clinical Neuropharmacology|February 27, 1999
L-Dopa-induced sedation: a double-blind cross-over controlled study versus triazolam and placebo in healthy volunteersN Andreu, J J Chalé, J M Senard, et al.
Pageof 22